nbi-1117568
Small moleculeexperimental
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
6
Phase 3
4
Phase 4
0
Earliest trial started Oct 4, 2022 (NCT05545111)
Timeline
Indications
Studied for
Mechanism of action
- Muscarinic acetylcholine receptor M4ANTAGONIST
CHRM4 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07227818 | Phase 3 | Dec 31, 2025 | Neurocrine Biosciences |
| NCT07288320 | Phase 2 | Dec 31, 2025 | Neurocrine Biosciences |
| NCT07105098 | Phase 3 | Aug 11, 2025 | Neurocrine Biosciences |
| NCT07114874 | Phase 3 | Jul 11, 2025 | Neurocrine Biosciences |
| NCT06963034 | Phase 3 | May 8, 2025 | Neurocrine Biosciences |
| NCT05545111 | Phase 2 | Oct 4, 2022 | Neurocrine Biosciences |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Neurocrine Biosciences | For profit | 6 | 6 | 2 | 2022 |
1 organizations
Page 1 / 1